New drug cocktail aims to outdo chemo for tough throat cancer

NCT ID NCT06976190

Recruiting now Disease control Sponsor: Shanghai Miracogen Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests whether combining two drugs, MRG003 and pucotenlimab, works better than standard chemotherapy for people with nasopharyngeal cancer that has returned or spread. About 446 participants will be randomly assigned to receive either the new combo or one of three chemo drugs. The main goals are to see if the combo delays cancer growth and improves overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MRG003 and pucotenlimab (drug combination)
What this could lead to: If successful, this combination could offer a new treatment option for people with nasopharyngeal cancer that has come back or spread, potentially improving survival compared to standard chemotherapy.
What could go wrong: This is an early-stage Phase 3 trial, so results are not yet known. The combination may not work better than chemotherapy and could have side effects like immune-related reactions or infusion reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nasopharyngeal carcinoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510060, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.